Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 12,833

Document Document Title
WO/2018/070734A1
The present invention relates to a marking material having a contrasting effect and tissue adhesion characteristics and comprising core/shell nanoparticles, which are structured to comprise a core having a contrasting effect and a silica...  
WO/2018/069329A1
Provided is a process of producing activated particles comprising 188Re-isotopes and/or 186Re-isotopes by irradiating non-volatile and water-insoluble starting particles comprising a rhenium compound with neutrons. Further provided is a ...  
WO/2018/071911A1
This disclosure relates to nanoparticles comprising a surface molecule that binds or blocks PD-L1. In certain embodiments, the disclosure relates to methods of using peptides or nanoparticles disclosed herein for the treatment of cancer....  
WO/2018/067361A1
This disclosure relates to synthetic ligands for detecting PD-L1 in a sample or subject. The ligand can be labeled with a variety of detectable labels allowing of visualization and quantification. The ligand provides an alternative PD-L1...  
WO/2018/067991A1
Dysfunctional or exhausted T cells arise in chronic diseases including chronic viral infections and cancer, and express high levels of co-inhibitory receptors. Therapeutic blockade of these receptors has clinical efficacy in the treatmen...  
WO/2018/068060A1
Compositions and methods of using these compositions that can include a targeting moiety and a therapeutic agent are described herein. These compositions can be used for di-agnosing and/or treating flaviviridae-family viruses including Z...  
WO/2018/067751A1
The present invention is directed to compositions and methods related to carbohydrate-based backbone CD206-targeting molecules. Described herein are compositions for diagnosing and treating disorders, for example but without limitation, ...  
WO/2018/063638A1
Provided herein are a variety of metal chelators as well as methods of use thereof.  
WO/2018/057635A1
A shielding assembly may be used in a nuclear medicine infusion system that generates and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the shielding assembly has multiple compartme...  
WO/2018/057915A1
Provided here are compositions comprising engineered lymphocytes that secrete bispecific engager molecules, thereby activating T cells in the local environment to kill target cells. In particular embodiments, engineered lymphocytes selec...  
WO/2018/055316A1
The invention relates to compounds of formula (II) for using in imaging and particularly for the diagnosis of neurodegenerative diseases.  
WO/2018/057636A1
An infusion system may include a strontium-rubidium radioisotope generator that generates a radioactive eluate via elution, a beta detector, a gamma detector, and a controller. The beta detector and the gamma detector may be positioned t...  
WO/2018/057634A1
A nuclear medicine infusion system (10) may be used to generate and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the infusion system includes a frame (30) that carries a radioisoto...  
WO/2018/050851A1
The disclosure relates to the use of 177Lu-lilotomab satetraxetan in the treatment of Non-Hodgkin lymphoma. Aspects included are specific administration patterns, with specific concentrations, pre-treatments and predosing.  
WO/2018/052818A1
Provided are anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-1 antibodies or antigen binding fragments thereof, related expression vectors, and host c...  
WO/2018/053316A1
Methods and compositions are provided for hybrid telodendrimers and nanocarriers containing such hybrid telodendrimers.  
WO/2018/048882A1
The present invention provides a composition comprising the compound having the structure: Formula or a salt of the compound; 4-amino-2- [19F] -fluorobenzoic acid or a salt of 4-amino-2- [19F] -fluorobenzoic acid; and at least one accept...  
WO/2018/049129A1
Compounds are described herein where CCK2R targeting ligands are attached to an imaging agent through a linker. The compounds can be used in the detection, diagnosis, imaging and treatment of cancer.  
WO/2018/048879A1
A variety of compounds are provided capable of chelating a metal, in particular a lanthanide such as Eu(III) and Tb(III). Luminescent complexes of the compound and a metal ion are also provided, in particular luminescent metal complexes ...  
WO/2018/048856A1
A method of radiolabeling a biomolecule using a microfluidic device includes loading one or more droplets containing a 18F-labeled prosthetic group on or into the microfluidic device and evaporating the droplet(s) containing the 18F-labe...  
WO/2018/048928A1
Described herein are probe compounds that interact with the LOXL2 receptor, methods of making such probe compounds, and methods of using such probe compounds in vitro and in vivo.  
WO/2018/045464A1
Bifunctional molecules having first and second alpha-synuclein binding agents coupled by a linker are disclosed. The bifunctional molecules have potential utility in the diagnosis, treatment and/or prophylaxis of disorders in which alpha...  
WO/2018/048873A2
A method of formulating or concentrating a radiolabeled molecule or compound includes providing a microfluidic device having a sample layer containing a microfluidic channel formed therein, a porous membrane having a pore size of less th...  
WO/2018/042018A3
The present invention relates to an approach for the treatment of adverse neurological sensations in a certain body surface area such as the skin, in particular treatment of pain or itching. The invention is based on the finding that adm...  
WO/2018/042018A2
The present invention relates to an approach for the treatment of adverse neurological sensations in a certain body surface area such as the skin, in particular treatment of pain or itching. The invention is based on the finding that adm...  
WO/2018/043932A1
The present invention provides a composition for preventing and treating a dental pulp disease. The pharmaceutical composition for preventing and treating a dental pulp disease according to an embodiment of the present invention reduces ...  
WO/2018/044534A1
The present invention is directed to transduced T cells expressing at least 100,000 molecules of human somatostatin receptor 2 (SSTR2), which improves PET/CT imaging sensitivity. The present invention is also directed to transduced T cel...  
WO/2018/044812A2
Siderocalin-metal chelator combinations that bind metallic radioisotopes used in nuclear medicine with high affinity are described. The high affinity siderocalin-metal chelator combinations include a number of chelator backbone arrangeme...  
WO/2018/042385A3
Disclosed are compositions comprising an isolated chimeric interleukin 6 receptor alpha (IL-6Rα) binding protein or cells expressing an isolated chimeric IL-6Rα binding protein. The isolated IL-6Rα chimeric binding protein and cells e...  
WO/2018/039662A1
Methods for rapid isolation of radionuclides (e.g., 68Ga) produced using a cyclotron and methods for recycling of the parent isotope (e.g., 68Zn) are disclosed. In one version of the method, a solution including a radionuclide (e.g., 68G...  
WO/2018/039602A1
The present invention provides materials and methods for using electrical stimulation to treat a mammal having a proteinopathy (e.g., neurodegenerative diseases) or at risk of developing a proteinopathy are provided. For example, the pre...  
WO/2018/035610A1
The present invention provides 18F-labeled amino acids or derivatives thereof having formula (I) and methods of making same, which can be suitable for PET imaging: (Formula (I)).  
WO/2018/032104A1
The present invention relates to a novel family of covalent kinases inhibitors, compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly ITK and/or TXK, BTK, TEC and/or co...  
WO/2018/035013A1
Gallium-68 generators that are capable of producing gallium-68 from a germanium-68 source material are disclosed. The source material may be a matrix material (e.g., zeolite) in which germanium-68 is isomorphously substituted for central...  
WO/2018/034354A1
Provided is a composition containing a buffer, the composition being used when a chelation targeting agent is labeled by 90Y, 153Sm, 165Dy, 165Er, 166Ho, or 177Lu. One or more buffers selected from benzoic acid, maleic acid, fumaric acid...  
WO/2018/035084A1
The invention provides monovalent, asymmetric tandem Fab bispecific antibodies that can bind two epitopes or two antigens, compositions comprising such antibodies, uses of such antibodies, methods of making such antibodies, nucleic acids...  
WO/2018/028645A1
A medical yttrium-90 (90Y) carbon microsphere used for the treatment of tumours, and a preparation method therefor. The medical yttrium-90 series of carbon microspheres uses a series of carbon microspheres to adsorb a 90YCl3 solution and...  
WO/2018/028642A1
Provided are a medical iodine-131 carbon microsphere and method for fabrication thereof, used for tumor radiotherapy or tumor early-imaging diagnosis. The medical iodine-131 carbon microsphere is formed by using a carbon microsphere to a...  
WO/2018/031809A1
Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. Also provided are compositions including a compound of Formula (I) together with a pharmaceutically acceptable carrier, and methods for imaging p...  
WO/2018/028644A1
A medical yttrium phosphate carbon microsphere for use in tumor treatment and a preparation method therefor. A medical yttrium phosphate carbon microsphere for use in tumor treatment and a preparation method therefor. The medical yttrium...  
WO/2018/028643A1
A medical phosphorus-32 carbon microsphere for use in cancer treatment and a preparation method therefor. The medical phosphorus-32 carbon microsphere is prepared as follows: using carbon microspheres to absorb an yttrium tartrate comple...  
WO/2018/024643A1
The invention relates to 9H-pyrrolo-dipyridine derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as radiopharmaceuticals in particular as imaging agents for the detection ...  
WO/2018/024237A1
Disclosed is a nanobody against the human programmed death factor PD-L1. The antibody has the function of blocking the binding of PD-L1 to the receptor PD-1. Disclosed are the nanobody and the gene sequence encoding the nanobody, the cor...  
WO/2018/024789A1
The present invention describes a compound of formula (I) which can be used in the diagnosis, treatment or prevention of neurotensin receptor-related conditions such as tumors and hematological malignancies.  
WO/2018/022809A1
Provided herein is a method and system for analyzing a sample. In some embodiments the method makes use of a plurality of capture agents that are each linked to a different oligonucleotide and a corresponding plurality of labeled nucleic...  
WO/2018/022571A1
The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within...  
WO/2018/022929A1
Provided herein are kits, compositions, and methods for treatment of a disease, disorder, or condition, such as a proliferative disease, disorder, or condition. One aspect provides a composition including a radioisotope and a substrate. ...  
WO/2018/022990A1
The present invention is related to methods and apparatus for standardizing the geometric placement and measurement of a radioactive source relative to a radioactivity measurement device, and can be used in application of clinical radiop...  
WO/2018/022125A1
Alkylphosphocholine analogs incorporating a chelating moiety that chelates a radioactive metal isotope are disclosed herein. The alkylphophocholine analogs, which can be used to treat or detect solid tumors, have the formula: [Formula sh...  
WO/2018/015307A1
The present invention relates to novel, selective radiolabelled tau ligands which are useful for imaging and quantifying tau aggregates, using positron-emission tomography (PET). The invention is also directed to compositions comprising ...  

Matches 1 - 50 out of 12,833